DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al. · Paper published 1 Oct 2026
In a preprint analyzing 18,859 human participants from the Generation Scotland cohort, researchers evaluated Methylation-associated Gene Expression (MaGE) predictors. These tools use whole-blood DNA methylation proxies for p14ARF, p16INK4A, and p21CIP1 expression, as well as a composite score. Across the cohort, MaGE identified 45 Bonferroni-significant associations spanning 18 incident diseases and all-cause mortality. The two strongest links reflected the known tissue specificity of senescence activation: MaGE-p21 associated with incident alcoholic liver disease, while MaGE-p16 associated with pulmonary fibrosis. In a separate study, MaGE tracked clinical disease severity and treatment response in patients with Crohn's disease.
Why it matters
Cellular senescence is a key driver of aging, but studying it has traditionally required invasive, tissue-specific biopsies. Scalable blood-based markers allow researchers to monitor senescence at population scale and may aid patient selection in senolytic clinical trials.
Caveats
The study is an observational preprint that has not yet undergone peer review. The findings rely on blood-derived proxies rather than direct tissue measurements of senescence-marker expression.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
Methylation-associated Gene Expression (MaGE): a non-invasive, in vivo measure of cellular senescence
Simpson DJ, Crofts SJ, Mavrommatis C et al.
medRxiv · 1 Oct 2026 · Preprint, not yet peer-reviewed
- Relevance
- Core geroscience
- News value
- Important
- Evidence
- Humans
- Status
- Preprint
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.
Lactate receptor activation reduces cellular senescence and protects vascular health in mice
Loss of the lactate receptor GPR81 drives arterial senescence and lipid accumulation, while pharmacological stimulation restores vascular homeostasis in progeroid mice.
bioRxiv · Wu Y et al.